DrugPatentWatch Database Preview
Drugs in Development Information for Ecopipam
» See Plans and Pricing
What is the development status for investigational drug Ecopipam?
Ecopipam is an investigational drug.
There have been 11 clinical trials for Ecopipam.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2012.
The most common disease conditions in clinical trials are Syndrome, Tourette Syndrome, and Self-Injurious Behavior. The leading clinical trial sponsors are Psyadon Pharma, Emalex Biosciences Inc., and University of California Riverisde School of Medicine.
There are twelve US patents protecting this investigational drug and three hundred and fourteen international patents.
Summary for Ecopipam
| US Patents | 12 |
| International Patents | 314 |
| US Patent Applications | 18 |
| WIPO Patent Applications | 295 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2012-12-01) |
| Vendors | 11 |
Recent Clinical Trials for Ecopipam
| Title | Sponsor | Phase |
|---|---|---|
| Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely) | Premier Research Group plc | Phase 2 |
| Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely) | University of California, Riverside | Phase 2 |
| Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely) | Emalex Biosciences Inc. | Phase 2 |
Clinical Trial Summary for Ecopipam
Top disease conditions for Ecopipam
Top clinical trial sponsors for Ecopipam
US Patents for Ecopipam
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ecopipam | Start Trial | Tape preparation of WT1 peptide cancer vaccine for transdermal administration | NITTO DENKO CORPORATION (Osaka, JP) OSAKA UNIVERSITY (Osaka, JP) | Start Trial |
| Ecopipam | Start Trial | WT1 peptide cancer vaccine composition for mucosal administration | NITTO DENKO CORPORATION (Osaka, JP) OSAKA UNIVERSITY (Osaka, JP) | Start Trial |
| Ecopipam | Start Trial | WT1 peptide cancer vaccine composition for transdermal administration | NITTO DENKO CORPORATION (Osaka, JP) OSAKA UNIVERSITY (Osaka, JP) | Start Trial |
| Ecopipam | Start Trial | Process for synthesis of D1 receptor antagonists | Schering Corporation (Kenilworth, NJ) | Start Trial |
| Ecopipam | Start Trial | Active agent delivery systems and methods for protecting and administering active agents | New River Pharmaceuticals Inc. (Radford, VA) | Start Trial |
| Ecopipam | Start Trial | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | Schering Corporation (Kenilworth, NJ) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ecopipam
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ecopipam | Canada | CA2841014 | 2033-02-05 | Start Trial |
| Ecopipam | China | CN103961305 | 2033-02-05 | Start Trial |
| Ecopipam | European Patent Office | EP2762156 | 2033-02-05 | Start Trial |
| Ecopipam | India | IN393CH2014 | 2033-02-05 | Start Trial |
| Ecopipam | Japan | JP2014169279 | 2033-02-05 | Start Trial |
| Ecopipam | Japan | JP6512569 | 2033-02-05 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
